glp 1 non alcoholic fatty liver GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis GLP-1 and fatty liver disease.

Among Medicare enrollees who are overweight or obese, that number rises to one in four

While these drugs may provide immediate results, the goal is for patients to maintain their those results over time, even after stopping the medication

Appetite suppression and lower calorie intake without a robust protein and strength program can lead to disproportionate lean mass loss, which reduces resting metabolic rate, functional strength, and glucose disposal capacity

For many people, this supports thinking of treatment as ongoing rather than short-term

However, many gastrointestinal issues may be resolved once the medication is stopped or the dosage is lowered

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease